Cipla USA, Inc. is voluntarily recalling 1,180 boxes of Lanthanum Carbonate (1000mg) chewable tablets because the medication failed stability specifications for a hardness test. This prescription medication, manufactured by InvaGen Pharmaceuticals and distributed under both the Cipla and Exelan labels, may not perform as intended due to these quality issues. Consumers who have these tablets should check their packaging for specific lot numbers and expiration dates provided below.
The tablets failed a hardness test during stability monitoring, which could affect how the medication breaks down or is absorbed by the body. While no specific injuries have been reported, medications that do not meet quality specifications may not provide the expected therapeutic effect.
You have 2 options:
Manufactured by: Invagen Pharmaceuticals, Inc., Hauppauge, NY 11786. Recall #: D-0217-2026. Quantity: 1180 boxes.
Manufactured by: Invagen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd). Recall #: D-0218-2026.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.